The SynBio Biotech, Deinove (France), is hoping to break into the Carotenoid market for food, cosmetics and animal feed. Now, with their Deinococcus platform they have made several major advancements in their endeavours.
Deinococcus bacteria naturally produce these carotenoids, which have a high-added value (as precursors to vitamin A and as antioxidants). Today, the molecules are sold in a wide range of Industrial sectors and it is estimated that the market will reach €1.6Bn by 2019.
About 75% of existing production consists of petroleum derivatives; the rest is produced by plant extraction (such as in algae or Tomatoes) – ‘the fastest growing sector’, particularly benefiting from consumer demand (which want more ‘Natural’ products).
Through genetic engineering of Deinococcus bacteria, Deinove can achieve significantly high levels of production, giving it a real competitive advantage.
Deinove’s team worked on the characterisation of a 6,000-strain bank, which gave rise to a palette of various carotenoids, some of which were completely unique. This is the case of Deinoxanthin, a new carotenoid with potentially very important antioxidants properties.
So What Exactly has Deinove Achieved?
Optimization of the strain by the high-throughput genetic engineering platform has increased product yields by 6 to 8 fold, essentially a successful example of scaling-up (a real challenge in Synthetic Biology production and the key thing that matters in this industry).
Deinove has also since identified the terminal enzymes involved in the production of different carotenoids, and this has allowed the production of three additional molecules of the same family. This could eventually even lead to an increase in the number of target markets.
So what really remains now is for Deinove to optimise final yield volumes and refine how the carotenoids are extracted for a market finish. Great news, for this Green-Clean-Biotech all-rounder.